Advertisement

Annals of Hematology

, Volume 64, Issue 1, pp 35–39 | Cite as

Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients

  • B. Kemkes-Matthes
  • H. Bleyl
Original Article

Summary

Coagulation activation frequently occurs in cancer patients, resulting in thromboembolic complications and/or intravascular coagulation activation. The mechanisms leading to these alterations still are poorly understood. One explanation for the coagulation activation in malignant diseases is the presence of a direct factor X-activating cancer procoagulant.

Coagulation activation in lung cancer patients develops at earlier stages than factor X activation; we demonstrated increased factor IXiAT complexes in addition to elevated TAT complexes. The increases of factor IXiAT complexes were not dependent upon the stage of the disease. In contrast, TAT complexes were higher in patients suffering from advanced pulmonary non-small cell carcinoma than in patients with limited disease. In conclusion, coagulation activation in pulmonary cancer patients occurs at earlier steps in the coagulation cascade than factor X activation. While this activation is not dependent upon the stage of the disease, the observation that TAT complexes showed higher elevations in patients with advanced than in those with limited pulmonary nonsmall cell carcinoma could be an indication of a cancer procoagulant that directly activates factor X.

Key words

Factor IXiAT complex TAT complex Protein C Coagulation activation Lung cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ambrus JL, Ambrus CM, Mink IB, Pickren JW (1975) Causes of death in cancer patients. J Med: 61–64Google Scholar
  2. 2.
    Bauer KA, Rosenberg RD (1984) Thrombin generation in acute promyelocytic leukemia. Blood 64: 791–796PubMedGoogle Scholar
  3. 3.
    Bleyl H, Róka L (1990) Nachweis von Umsatzprodukten aktivierter Gerinnungsfaktoren. Med Welt 41: 927–932Google Scholar
  4. 4.
    Boisclair MD, Ireland H, Lane DA (1990) Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 4: 25–40PubMedGoogle Scholar
  5. 5.
    Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N (1979) Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 40: 228–233PubMedGoogle Scholar
  6. 6.
    Dvorak HF (1987) Thrombosis and cancer. Human Pathol 18: 275–284Google Scholar
  7. 7.
    Edwards RL, Rickles FR, Cronlund M (1981) Abnormalities of blood coagulation in patients with cancer. J Lab Clin Med 98: 917–928PubMedGoogle Scholar
  8. 8.
    Edwards RL, Rickles FR, Moritz ThE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnell JF, Headley E, Kim S-H, O'Dell R, Tornyos K, Kwaan HC (1987) Abnormalities of blood coagulation tests in patients with cancer. J Clin Pathol 88: 596–602Google Scholar
  9. 9.
    Falanga A, Gordon SG (1985) Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochem 24: 5558–5567PubMedGoogle Scholar
  10. 10.
    Gordon SG (1981) A proteolytic procoagulant associated with malignant transformation. J Histochem Cytochem 29: 457–463PubMedGoogle Scholar
  11. 11.
    Gordon SG, Benson B (1989) Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 56: 431–440PubMedGoogle Scholar
  12. 12.
    Gordon SG, Cross BA (1981) A factor-X-activating thiol protease from malignant tissue. J Clin Invest 67: 1665–1671PubMedGoogle Scholar
  13. 13.
    Gordon SG, Lewis BJ (1978) Comparison of procoagulants from normal and transformed fibroblasts. Cancer Res 38: 2467–2472PubMedGoogle Scholar
  14. 14.
    Gordon SG, Franks JJ, Lewis B (1975) Cancer procoagulant A: a factor-X-activating procoagulant from malignant tissue. Thromb Res 6: 127–137PubMedGoogle Scholar
  15. 15.
    Gordon SG, Franks JJ, Lewis BJ (1979) Comparison of procoagulants from normal and malignant human tissue. J Natl Cancer Inst 62: 773–776PubMedGoogle Scholar
  16. 16.
    Gordon SG, Hasiba U, Poole MA, Cross BA, Falanga A (1985) A cysteine proteinase procoagulant from amnion-chorion. Blood 66: 1261–1265PubMedGoogle Scholar
  17. 17.
    Hagedorn AB, Bowie EJW, Elveback LR, Owen CA (1974) Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 49: 649–653Google Scholar
  18. 18.
    Lindahl AK, Sandset PM, Abildgaard U (1990) Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Haemostasis 20: 253–262PubMedGoogle Scholar
  19. 19.
    Miller SP, Sanchez-Avalos J, Stefanski T, Zuckerman L (1967) Coagulation disorders in cancer. Cancer 20: 1452–1465PubMedGoogle Scholar
  20. 20.
    Mombelli G, Monotti R, Haeberli A, Straub PW (1987) Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thrombo-embolic diseases. Thromb Haemost 58: 758–763PubMedGoogle Scholar
  21. 21.
    Müller-Berghaus G (1989) Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 15: 58–87PubMedGoogle Scholar
  22. 22.
    Nanninga PB, van Teunenbroek A, Veenhof CHN, Büller HR, ten Cate JW (1990) Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost 64: 361–364PubMedGoogle Scholar
  23. 23.
    Peuscher FW, Cleton FJ, Armstrong L, Stoepman-van Dalen EA, van Mourik JA, van Aken WG (1980) Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 96: 5–14PubMedGoogle Scholar
  24. 24.
    Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62: 14–31PubMedGoogle Scholar
  25. 25.
    Rickles FR, Edwards RL, Barb C, Cronlund M (1983) Abnormalities of blood coagulation in patients with cancer. Cancer 51: 301–307PubMedGoogle Scholar
  26. 26.
    Rickles FR, Hancock WW, Edwards RL, Zacharski LR (1988) Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost 14: 88–94Google Scholar
  27. 27.
    Rocha E, Páramo JA, Fernández FJ, Cuesta B, Hernández M, Paloma MJ, Rifón J (1989) Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 54: 699–707PubMedGoogle Scholar
  28. 28.
    Schröck R, Hafter R, Schmid L, Babic R, Ulm K, Gössner W, Graeff H (1986) Tumorassoziierte Antigene und Fibrinderivate als Reaktionsprodukte des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 46: 1–10PubMedGoogle Scholar
  29. 29.
    Sproulw EE (1983) Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 34: 566–585Google Scholar
  30. 30.
    Sun NCJ, McAfee WM, Hum GJ, Weiner JM (1979) Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 71: 10–16PubMedGoogle Scholar
  31. 31.
    Tatra G, Reinthaller A (1991) Elevated thrombin-antithrombin III complex concentrations in patients with gynaecological malignancy. Klin Wochenschr 69: 124–127Google Scholar
  32. 32.
    Uchiyama T, Matsumoto M, Kobayashi N (1990) Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 59: 955–965PubMedGoogle Scholar
  33. 33.
    Viganò S, Mannucci PM, D'Angelo A, Gelfi C, Gensini GF, Rostagno C, Neri Serneri GG (1984) Protein C antigen is not an acute-phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost 52: 263–266PubMedGoogle Scholar
  34. 34.
    Yoda Y, Abe T (1981) Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 46: 706–709PubMedGoogle Scholar
  35. 35.
    Zurborn KH, Kirch W, Bruhn HB (1988) Immunological and functional determination of the protease inhibitors, protein C and antithrombin III, in liver cirrhosis and in neoplasia. Thromb Res 52: 325–336PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • B. Kemkes-Matthes
    • 1
  • H. Bleyl
    • 2
  1. 1.Zentrum für Innere Medizin der Universität GiessenGiessenFRG
  2. 2.Institut für Labordiagnostik der Städtischen Kliniken OffenbachOffenbach am MainFRG

Personalised recommendations